SLC5A2 and chronic kidney disease: In patients with CKD presenting with hyperkalemia where up-titration of RAAS blockade may be prohibited, SGLT2 inhibitors may enhance kaliuresis by increasing distal delivery of sodium and stimulating aldosterone, thereby reducing hyperkalemia (Yau et al., 2022).